DE69833554T2 - Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen - Google Patents
Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen Download PDFInfo
- Publication number
- DE69833554T2 DE69833554T2 DE69833554T DE69833554T DE69833554T2 DE 69833554 T2 DE69833554 T2 DE 69833554T2 DE 69833554 T DE69833554 T DE 69833554T DE 69833554 T DE69833554 T DE 69833554T DE 69833554 T2 DE69833554 T2 DE 69833554T2
- Authority
- DE
- Germany
- Prior art keywords
- taurolidine
- taurultam
- trocar
- solution
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229960004267 taurolidine Drugs 0.000 title claims abstract description 36
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 229950007343 taurultam Drugs 0.000 title claims abstract description 17
- 206010027476 Metastases Diseases 0.000 title claims description 19
- 239000003814 drug Substances 0.000 title claims description 6
- 238000002357 laparoscopic surgery Methods 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 14
- 238000001802 infusion Methods 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 abstract description 10
- 230000006510 metastatic growth Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 17
- 210000000683 abdominal cavity Anatomy 0.000 description 10
- 230000003211 malignant effect Effects 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000001015 abdomen Anatomy 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 208000005646 Pneumoperitoneum Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003815 abdominal wall Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002350 laparotomy Methods 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000002324 minimally invasive surgery Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022699 Intestinal stenosis Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000014174 Oesophageal disease Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000007453 hemicolectomy Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012830 laparoscopic surgical procedure Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Materials For Medical Uses (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9716219.2A GB9716219D0 (en) | 1997-07-31 | 1997-07-31 | Prevention of metastases |
| GB9716219 | 1997-07-31 | ||
| PCT/GB1998/002311 WO1999006114A2 (en) | 1997-07-31 | 1998-07-31 | Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69833554D1 DE69833554D1 (de) | 2006-04-27 |
| DE69833554T2 true DE69833554T2 (de) | 2006-08-10 |
Family
ID=10816777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69833554T Expired - Lifetime DE69833554T2 (de) | 1997-07-31 | 1998-07-31 | Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1001781B1 (OSRAM) |
| JP (2) | JP2001511463A (OSRAM) |
| AT (1) | ATE318141T1 (OSRAM) |
| DE (1) | DE69833554T2 (OSRAM) |
| ES (1) | ES2255172T3 (OSRAM) |
| GB (1) | GB9716219D0 (OSRAM) |
| WO (1) | WO1999006114A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9626795D0 (en) | 1996-12-23 | 1997-02-12 | Geistlich Soehne Ag | Combating infection in delivery systems |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US8304390B2 (en) | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US7132413B1 (en) | 1997-07-31 | 2006-11-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Anticoagulant/sterilizing compositions and methods |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| CA2302720C (en) * | 1999-03-29 | 2009-07-14 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Anticoagulant/sterilizing compositions and methods |
| US8030301B2 (en) | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US7892530B2 (en) | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| US7345039B2 (en) | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| CN100519525C (zh) | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| JP2003515558A (ja) * | 1999-12-06 | 2003-05-07 | ロード アイランド ホスピタル， ア ライフスパン パートナー | 腫瘍を治療するためのメチロール含有化合物の使用 |
| US6641571B2 (en) | 2000-01-05 | 2003-11-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| AU779362B2 (en) * | 2000-10-27 | 2005-01-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| US6753328B2 (en) * | 2001-10-01 | 2004-06-22 | Rhode Island Hospital | Methods of inhibiting metastases |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| CA2482687C (en) | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| CN101528195B (zh) * | 2006-09-07 | 2012-03-28 | 埃德盖斯特利希索恩化学工业股份公司 | 羟甲基转移剂在制备治疗骨癌的药物中的用途 |
| JP2021535167A (ja) * | 2018-08-31 | 2021-12-16 | コーメディクス・インコーポレーテッド | 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117A (ja) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | ムコ多糖系癌転移抑制剤 |
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| GB9400163D0 (en) * | 1994-01-06 | 1994-03-02 | Geistlich Soehne Ag | Membrane |
| DE19606897C2 (de) * | 1996-02-13 | 2002-08-29 | Geistlich Soehne Ag | Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren |
-
1997
- 1997-07-31 GB GBGB9716219.2A patent/GB9716219D0/en active Pending
-
1998
- 1998-07-31 WO PCT/GB1998/002311 patent/WO1999006114A2/en not_active Ceased
- 1998-07-31 ES ES98937635T patent/ES2255172T3/es not_active Expired - Lifetime
- 1998-07-31 DE DE69833554T patent/DE69833554T2/de not_active Expired - Lifetime
- 1998-07-31 EP EP98937635A patent/EP1001781B1/en not_active Expired - Lifetime
- 1998-07-31 AT AT98937635T patent/ATE318141T1/de active
- 1998-07-31 JP JP2000504921A patent/JP2001511463A/ja active Pending
-
2010
- 2010-02-12 JP JP2010029152A patent/JP2010215615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1001781A2 (en) | 2000-05-24 |
| WO1999006114A3 (en) | 1999-04-08 |
| GB9716219D0 (en) | 1997-10-08 |
| DE69833554D1 (de) | 2006-04-27 |
| JP2010215615A (ja) | 2010-09-30 |
| WO1999006114A2 (en) | 1999-02-11 |
| JP2001511463A (ja) | 2001-08-14 |
| ATE318141T1 (de) | 2006-03-15 |
| EP1001781B1 (en) | 2006-02-22 |
| ES2255172T3 (es) | 2006-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69833554T2 (de) | Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen | |
| DE68910138T2 (de) | Fumagillin als angiostatisches Mittel. | |
| Gianetta et al. | Hernia repair in elderly patients | |
| DE69024039T2 (de) | Behandlung von pathologischen zuständen und krankheiten. | |
| DE60024360T2 (de) | Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) | |
| CN101528218A (zh) | 治疗粘膜炎的组合物和方法 | |
| US7151099B2 (en) | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases | |
| Cook et al. | Use of systemically administered lidocaine in horses with gastrointestinal tract disease | |
| EP0337420A2 (de) | Dialysier- und Spüllösung für die intraperitoneale Verabreichung mit antimikrobieller Ausrüstung | |
| DE69813200T2 (de) | Verbesserung der wundheilung mit cm101/gbs-toxin | |
| DE19606897C2 (de) | Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren | |
| DE3152319C2 (de) | Verwendung einer Lösung eines Salzes der Alginsäure zur Behandlung von Strahlenschäden und Ulcera | |
| Salim | Use of scavenging oxygen‐derived free radicals to protect the rat against aspirin‐and ethanol‐induced erosive gastritis | |
| EP2237782B1 (de) | Verwendung von tetrahydropyrimidinen | |
| Wolma et al. | Treatment of injuries to the colon | |
| Selam et al. | Continuous peritoneal insulin infusion with portable pumps: factors affecting the operating life of the chronic catheter | |
| Lehr | Experimental and Clinical Studies with Sulfacetimide (p-Aminobenzenesulfonylacetylimide): Toxicity and Efficiency in Bacillary Infections of the Urinary Tract: I. Experimental Studies | |
| DE3238726A1 (de) | Phosphoramidderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten | |
| Rains | Biliary Obstruction in the Region of the Porta Hepatis: Hunterian Lecture delivered at the Royal College of Surgeons of England on 13th February 1958 | |
| Pradhan et al. | A clinical trial of hayatin methiodide as a relaxant in 100 cases | |
| Hooper et al. | Bacteremia producing shock following transurethral prostatectomy | |
| Memon et al. | Laparoscopic Closure of Acutely Perforated Duodenal-Ulcer-An Early Experience | |
| McCormack et al. | Oesophageal varices: evaluation of injection sclerotherapy without general anaesthesia using the flexible fibreoptic gastroscope | |
| Edwards et al. | Hernia through the Foramen of Winslow | |
| Garber | Strangulation in external hernia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |